دورية أكاديمية
Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance.
| العنوان: | Immunological Checkpoint Blockade in Anal Squamous Cell Carcinoma: Dramatic Responses Tempered By Frequent Resistance. |
|---|---|
| المؤلفون: | Jayakrishnan T; Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA., Yadav D; Department of Internal Medicine, Sinai Hospital of Baltimore, 2401 W Belvedere Ave, Baltimore, MD, 21215, USA., Huffman BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Cleary JM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. James_Cleary@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. James_Cleary@dfci.harvard.edu. |
| المصدر: | Current oncology reports [Curr Oncol Rep] 2024 Aug; Vol. 26 (8), pp. 967-976. Date of Electronic Publication: 2024 Jun 11. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Current Science Country of Publication: United States NLM ID: 100888967 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-6269 (Electronic) Linking ISSN: 15233790 NLM ISO Abbreviation: Curr Oncol Rep Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Philadelphia, PA : Current Science, c1999- |
| مواضيع طبية MeSH: | Immune Checkpoint Inhibitors*/therapeutic use , Anus Neoplasms*/therapy , Anus Neoplasms*/immunology , Carcinoma, Squamous Cell*/immunology , Carcinoma, Squamous Cell*/therapy , Carcinoma, Squamous Cell*/drug therapy, Humans ; Drug Resistance, Neoplasm ; Immunotherapy/methods ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Tumor Microenvironment/immunology ; B7-H1 Antigen/antagonists & inhibitors |
| مستخلص: | Purpose of Review: Squamous cell carcinoma of the anus (SCCA) is an HPV-associated malignancy that has limited treatment options. Immunotherapy has expanded these options and here we review current and emerging immunotherapeutic approaches. Recent Findings: Multiple studies of single-agent anti-PD1/PD-L1 immunotherapy have demonstrated a modest response rate of approximately 10% to 15%. While a minority of patients (~5%) with SCCA experience durable complete responses, most advanced SCCAs are resistant to anti-PD1/PD-L1 monotherapy. Given the need for more broadly effective immunotherapies, novel strategies, such as adaptive cell therapies and therapeutic vaccination, are being explored. To reduce the recurrence risk of localized high-risk SCCA, strategies combining immunotherapy with chemoradiation are also being investigated. While a small subset of patients with SCCA have prolonged responses to PD1-directed immunotherapy, the majority do not derive clinical benefit, and new immunotherapeutic strategies are needed. Better understanding of the immune microenvironment and predictive biomarkers could accelerate therapeutic advances. (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| فهرسة مساهمة: | Keywords: Adoptive Cell Therapy; Anal Squamous Cell Carcinoma; Human Papilloma Virus; Immune Checkpoint Inhibitor; Immunotherapy; Therapeutic Vaccination |
| المشرفين على المادة: | 0 (Immune Checkpoint Inhibitors) 0 (Programmed Cell Death 1 Receptor) 0 (B7-H1 Antigen) 0 (PDCD1 protein, human) |
| تواريخ الأحداث: | Date Created: 20240611 Date Completed: 20240805 Latest Revision: 20240805 |
| رمز التحديث: | 20240805 |
| DOI: | 10.1007/s11912-024-01564-z |
| PMID: | 38861124 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1534-6269 |
|---|---|
| DOI: | 10.1007/s11912-024-01564-z |